Bank of America’s Maze Therapeutics MAZE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$5.82M Buy
195,084
+176,703
+961% +$7.8M ﹤0.01% 3343
2025
Q4
$762K Buy
18,381
+8,807
+92% +$303K ﹤0.01% 4675
2025
Q3
$248K Buy
9,574
+3,792
+66% +$64K ﹤0.01% 6175
2025
Q2
$70.9K Buy
5,782
+1,455
+34% +$15.1K ﹤0.01% 6674
2025
Q1
$47.6K Buy
+4,327
New +$52.1K ﹤0.01% 6760

Other funds holding MAZE

Bank of America's MAZE Position: Q1 2026 in Review

Bank of America increased its Maze Therapeutics (MAZE) stake by 961% in Q1 2026, buying an estimated $7.8M and bringing the position to 195,084 shares worth $5.82M. The position accounts for ﹤0.01% of the portfolio, ranked #3343.

Bank of America first reported a position in MAZE in Q1 2025 and has held it in 5 quarters since. 165 funds tracked by Wall St. Rank hold MAZE as of Q1 2026.

  • Bank of America held 195,084 shares of Maze Therapeutics worth $5.82M as of Q1 2026.
  • Bank of America bought 176,703 Maze Therapeutics shares in Q1 2026, an estimated $7.8M.
  • Maze Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #3343 holding.
  • Bank of America first reported a position in Maze Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 165 funds tracked by Wall St. Rank held Maze Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.